Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Rahway, New Jersey Thursday, July 3, 2025, 09:00 Hrs [IST] ...

Key Takeaways The S&P 500 added 0.8% on Thursday, July 3, 2025, reaching a record closing high as a strong jobs report helped ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

UBS reaffirmed its Buy rating and $105 target for Merck, brushing off investor pessimism about the pharmaceutical giant’s ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. TaxStatus is the only firm to provide the comprehensive information advisors need to ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immunotherapies in the disease ...

Bayer and Merck & Co’s heart failure drug vericiguat has been approved by the FDA under the brand name Verquvo, in an increasingly competitive market.